Produktresuméet er ændret i overensstemmelse hermed, og det bemærkes i produktresuméet under pkt.
The SPC has been amended accordingly and notes in section 5.1 that, for patients with locally advanced disease “ A reduction in risk of objective disease progression… was most evident in those at highest risk of disease progression.